Iterum Therapeutics – $80 Million IPO

San Diego – June 8, 2018 – Cooley advised Iterum Therapeutics plc on its $80 million initial public offering of 6,150,000 ordinary shares. The underwriters have a 30-day option to purchase up to an additional 922,500 shares. Cooley partners Charlie Kim and Alan Hambelton led the team advising Iterum.

Leerink Partners and RBC Capital Markets acted as joint book-running managers for the offering. Guggenheim Securities acted as lead manager. Needham & Company acted as co-manager.

Iterum is an Irish clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. The company’s shares now trade on the Nasdaq Global Market under the symbol “ITRM.”

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 900+ lawyers across 13 offices in the United States, China and Europe.

Related Contacts
Charlie Kim Partner, San Diego
Alan Hambelton Partner, Seattle
Colleen Badgley Associate, Seattle
Julia Stark Associate, Seattle
Shivani Agarwal Associate, Seattle
Brian Woodard Paralegal Specialist, Seattle
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Rena Kaminsky Special Counsel, Palo Alto
Erin Umberg Associate, Palo Alto
Bill Christiansen Partner, Seattle
Aaron Nudelman Associate, Seattle
Mark Windfeld-Hansen Partner, Palo Alto
Susan Cooper Philpot Retired Partner, San Francisco
John McKenna Partner, Palo Alto